On this page
Magnesium Sulfate
Magnesium Sulfate In Water For · Injection
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Magnesium Sulfate Heptahydrate | 40 mg/mL | 1658221 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Calculi Dissolution Agent [EPC] | EPC | All 33 members |
| Increased Large Intestinal Motility [PE] | PE | All 83 members |
| Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] | PE | All 83 members |
| Inhibition Small Intestine Fluid/Electrolyte Absorption [PE] | PE | All 30 members |
| Magnesium Ion Exchange Activity [MoA] | MoA | All 30 members |
| Osmotic Activity [MoA] | MoA | All 105 members |
| Osmotic Laxative [EPC] | EPC | All 103 members |
| Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] | PE | All 53 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 216597-001 | MAGNESIUM SULFATE IN PLASTIC CONTAINER | INJECTABLE | MAGNESIUM SULFATE | Prescription | AP | ||
| 216597-002 | MAGNESIUM SULFATE IN PLASTIC CONTAINER | INJECTABLE | MAGNESIUM SULFATE | Prescription | AP |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 1 | Labeling | Approved | July 12, 2023 | Standard |
| Original application | 1 | Approved | February 15, 2023 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250212). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Magnesium sulfate in water for injection is intended for intravenous use only. For the management of pre-eclampsia or eclampsia, intravenous infusions of dilute solutions of magnesium (1% to 8%) are often given in combination with intramuscular injections of 50% Magnesium Sulfate Injection, USP. Therefore, in the clinical conditions cited below, both forms of therapy are noted, as appropriate. Continuous maternal administration of magnesium sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities. In Eclampsia In severe pre-eclampsia or eclampsia, the total initial dose is 10 g to 14 g of magnesium sulfate. To initiate therapy, 4 g of Magnesium sulfate in water for injection may be administered intravenously. The rate of intravenous infusion should generally not exceed 150 mg/minute, or 3.75 mL of a 4% concentration (or its equivalent) per minute, except in severe eclampsia with seizures. Simultaneously, 4 g to 5 g (32.5 mEq to 40.6 mEq) of magnesium sulfate may be administered intramuscularly into each buttock using undiluted 50% Magnesium Sulfate Injection, USP. After the initial intravenous dose, some clinicians administer 1 g/hour to 2 g/hour by constant intravenous infusion. Subsequent intramuscular doses of 4 g to 5 g of magnesium sulfate may be injected into alternate buttocks every four hours, depending on the continuing presence of the patellar reflex, adequate respiratory function, and absence of signs of magnesium toxicity. Therapy should continue until paroxysms cease. A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 g to 40 g magnesium sulfate should not be exceeded. In the presence of severe renal insufficiency, frequent serum magnesium concentrations must be obtained and the maximum dosage of magnesium sulfate is 20 g per 48 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless solution is clear. Discard unused portion.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.
Warnings
openFDA Drug LabelingWARNINGS FETAL HARM: Continuous administration of magnesium sulfate beyond 5 to 7 days to pregnant women can lead to hypocalcemia and bone abnormalities in the developing fetus. These bone abnormalities include skeletal demineralization and osteopenia. In addition, cases of neonatal fracture have been reported. The shortest duration of treatment that can lead to fetal harm is not known. Magnesium sulfate should be used during pregnancy only if clearly needed. If magnesium sulfate is given for treatment of preterm labor, the woman should be informed that the efficacy and safety of such use have not been established and that use of magnesium sulfate beyond 5 to 7 days may cause fetal abnormalities. Parenteral use in the presence of renal insufficiency may lead to magnesium intoxication.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The adverse effects of parenterally administered magnesium usually are the result of magnesium intoxication. These include flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system depression proceeding to respiratory paralysis. Hypocalcemia with signs of tetany secondary to magnesium sulfate therapy for eclampsia has been reported.
Description
openFDA Drug LabelingDESCRIPTION Magnesium sulfate in water for injection is a sterile, nonpyrogenic, clear and colorless solution of magnesium sulfate heptahydrate, USP in water for injection, USP. May contain sulfuric acid and/or sodium hydroxide for pH adjustment. The pH is 4.5 (3.5 to 6.5). It is available in 4% concentration. See HOW SUPPLIED section for the content and characteristics of available dosage forms and sizes. Magnesium sulfate heptahydrate is chemically designated as MgSO 4 • 7H 2 O and its molecular weight is 246.5 g/mol and having below structural formula: Magnesium sulfate heptahydrate, USP is white or almost white crystalline powder or brilliant colorless crystals which is freely soluble in water, very soluble in boiling water, practically insoluble in ethanol (96%). Water for Injection, USP is chemically designated H 2 O. The flexible plastic container is fabricated from a specially formulated non polyvinylchloride. 12
Overdosage
openFDA Drug LabelingOVERDOSAGE Magnesium intoxication is manifested by a sharp drop in blood pressure and respiratory paralysis. Disappearance of the patellar reflex is a useful clinical sign to detect the onset of magnesium intoxication. In the event of overdosage, artificial ventilation must be provided until a calcium salt can be injected intravenous to antagonize the effects of magnesium. For Treatment of Overdose Artificial respiration is often required. Intravenous calcium, 10 mL to 20 mL of a 5% solution (diluted if desirable) with isotonic sodium chloride for injection) is used to counteract effects of hypermagnesemia. Subcutaneous physostigmine, 0.5 mg to 1 mg may be helpful. Hypermagnesemia in the newborn may require resuscitation and assisted ventilation via endotracheal intubation or intermittent positive pressure ventilation as well as intravenous calcium.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Magnesium Sulfate in Water for Injection is clear and colorless solution filled in intravenous bag and are supplied as 2 g/50 mL (40 mg/mL) and 4 g/100 mL (40 mg/mL). Each 50 mL contains 2 g of magnesium sulfate heptahydrate, USP (equivalent to 16.25 mEq magnesium) in water for injection and each 100 mL contains 4 g of magnesium sulfate heptahydrate, USP (equivalent to 32.5 mEq magnesium) in water for injection. It is available as follows: Strength Each Unit of Sale 2 g/50 mL (40 mg/mL) NDC 70121-1719-1 1 Single-dose Intravenous Bag in an Overwrap NDC 70121-1719-9 Unit of 24 NDC 70121-1719-2 Unit of 15 4 g/100 mL (40 mg/mL) NDC 70121-1720-1 1 Single-dose Intravenous Bag in an Overwrap NDC 70121-1720-9 Unit of 24 NDC 70121-1720-3 Unit of 12 For more details, please see below table: NDC No. Size Total Magnesium Sulfate Total Magnesium Ion Magnesium Sulfate Concentration Magnesium Ion Concentration Osmolarity (cal.) 70121-1719-1 50 mL 2 g 16.25 mEq 40 mg/mL 16.25 mEq/50 mL 325 mOsmol/Liter 70121-1720-1 100 mL 4 g 32.5 mEq 40 mg/mL 32.5 mEq/100 mL 325 mOsmol/Liter WARNING: DO NOT USE FLEXIBLE CONTAINER IN SERIES CONNECTIONS. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: MAGNESIUM SULFATE HEPTAHYDRATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class I | April 8, 2026 | Amneal Pharmaceuticals, LLC | Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead. | Ongoing |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 70121-1719-2 | 70121-1719 | Amneal Pharmaceuticals LLC | 15 POUCH in 1 CARTON (70121-1719-2) / 1 BAG in 1 POUCH / 50 mL in 1 BAG | January 8, 2024 |
| 70121-1719-9 | 70121-1719 | Amneal Pharmaceuticals LLC | 24 POUCH in 1 CARTON (70121-1719-9) / 1 BAG in 1 POUCH / 50 mL in 1 BAG | February 20, 2023 |
| 70121-1720-3 | 70121-1720 | Amneal Pharmaceuticals LLC | 12 POUCH in 1 CARTON (70121-1720-3) / 1 BAG in 1 POUCH / 100 mL in 1 BAG | January 8, 2024 |
| 70121-1720-9 | 70121-1720 | Amneal Pharmaceuticals LLC | 24 POUCH in 1 CARTON (70121-1720-9) / 1 BAG in 1 POUCH / 100 mL in 1 BAG | February 20, 2023 |
| 70121-1719 | 70121-1719 | Amneal Pharmaceuticals LLC | — | February 20, 2023 |
| 70121-1720 | 70121-1720 | Amneal Pharmaceuticals LLC | — | February 20, 2023 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.